MedTrace Logo

Megestrol in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

NCT00041275 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2013-09-20

No results posted yet for this study

Summary

RATIONALE: Estrogen can stimulate the growth of cancer cells. Hormone therapy using megestrol may fight liver cancer by blocking the uptake of estrogen. It is not yet known if megestrol is an effective treatment for liver cancer.

PURPOSE: Randomized phase III trial to determine the effectiveness of megestrol in treating patients who have liver cancer that cannot be removed by surgery.

Conditions

Interventions

DRUG

megestrol acetate

Sponsors & Collaborators

  • National Medical Research Council (NMRC), Singapore

    lead OTHER_GOV

Principal Investigators

  • Pierce Chow, MD, PhD, MBBS, FRCS, FAMS · National Cancer Centre, Singapore

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-05-31
Primary Completion
2007-06-30
Completion
2011-08-31

Countries

  • Bangladesh
  • Burma
  • Indonesia
  • New Zealand
  • Philippines
  • Singapore
  • South Korea
  • Taiwan
  • Thailand
  • Vietnam

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00041275 on ClinicalTrials.gov